AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $52.4444.

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Thursday, October 30th. Canaccord Genuity Group increased their price objective on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, JPMorgan Chase & Co. raised their target price on AtriCure from $42.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th.

Insider Transactions at AtriCure

In related news, Director Sven Wehrwein sold 5,033 shares of AtriCure stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $37.32, for a total value of $187,831.56. Following the completion of the sale, the director owned 34,374 shares of the company’s stock, valued at approximately $1,282,837.68. This trade represents a 12.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Justin J. Noznesky sold 5,166 shares of the company’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total transaction of $192,640.14. Following the sale, the insider directly owned 78,798 shares in the company, valued at approximately $2,938,377.42. This trade represents a 6.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 18,166 shares of company stock worth $676,378. 3.50% of the stock is owned by company insiders.

Institutional Trading of AtriCure

A number of institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its stake in AtriCure by 19.5% in the 1st quarter. Invesco Ltd. now owns 52,162 shares of the medical device company’s stock valued at $1,683,000 after buying an additional 8,515 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of AtriCure by 103.5% in the first quarter. Raymond James Financial Inc. now owns 247,436 shares of the medical device company’s stock worth $7,982,000 after acquiring an additional 125,845 shares during the period. Trexquant Investment LP grew its position in shares of AtriCure by 180.6% in the first quarter. Trexquant Investment LP now owns 275,548 shares of the medical device company’s stock valued at $8,889,000 after purchasing an additional 177,342 shares in the last quarter. Panagora Asset Management Inc. raised its stake in shares of AtriCure by 3.7% during the 1st quarter. Panagora Asset Management Inc. now owns 214,551 shares of the medical device company’s stock valued at $6,921,000 after purchasing an additional 7,684 shares during the period. Finally, Paradigm Capital Management Inc. NY raised its stake in shares of AtriCure by 14.7% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 123,100 shares of the medical device company’s stock valued at $3,971,000 after purchasing an additional 15,800 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Up 0.1%

Shares of NASDAQ:ATRC opened at $40.59 on Thursday. AtriCure has a 1 year low of $28.29 and a 1 year high of $43.11. The company has a market capitalization of $2.02 billion, a PE ratio of -66.53 and a beta of 1.47. The business has a fifty day moving average price of $36.68 and a two-hundred day moving average price of $35.07. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.85.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. The company had revenue of $134.27 million for the quarter, compared to the consensus estimate of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Analysts forecast that AtriCure will post -0.6 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.